Phase II Study of Oral Azacitidine (CC-486) in Combination with Pembrolizumab (MK-3475) in Patients with Metastatic Melanoma
You are being asked to take part in this study because you have advanced melanoma. The goal of this clinical research study is to learn if oral azacitidine (CC-486) and pembrolizumab (MK-3475) can help to control melanoma. The safety of this drug combination will also be studied.
Disease Group: Melanoma and other malignant neoplasms of skin
Treatment Agent: Azacitidine,Pembrolizumab
Treatment Location: Only at MDACC
Primary Objective: To determine the safety and efficacy of the combination of oral azacitidine and pembrolizumab (CC-486 + MK-3475) as defined by Objective Response Rate (ORR) by RECIST 1.1 in patients with metastatic melanoma that are PD-1 naïve (Arm A) or that have progressed on PD-1 directed therapy (Arm B). Secondary Objectives & Hypotheses Objectives To determine the safety and tolerability of the combination of CC-486 + MK-3475 in patients with melanoma. To determine the Progression-Free and overall survival. To determine the incidence of grade 3 and 4 immune-related adverse events. To compare the objective response rate of the combination as determined by RECIST and the immune related Response Criteria (ir-RC). To determine the pharmacodynamic effects of the combination on: Expression of Cancer Testis Antigens in PBMCs and tumor tissues. Myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs). Hypothesis Objective: We hypothesize that the improved clinical outcome will be mediated by re-expression of Cancer Testis Antigens (CTA) and/or augmentation of the effect of on Myeloid-derived Suppressor Cells (MDSCs) and Regulatory T cells (Tregs).
IRB Review and Approval Date: 02/14/2017
Recruitment Status: Open
Projected Accrual: N/A
1) Patients who have unresectable Stage III through stage IV metastatic
melanoma that have not received prior PD-1 directed therapy (Arm A) or
that have progressed despite prior PD-1 directed therapy (Arm B).
2) Be willing and able to provide written informed consent/assent for the trial.
3) Be >/= 18 years of age on day of signing informed consent.
4) Have measurable or evaluable disease based on RECIST 1.1.
5) Be willing to provide archival or fresh tissue from a newly obtained core or excisional biopsy of a tumor lesion. Newly-obtained is defined as a specimen obtained up to 4 weeks (28 days) prior to initiation of treatment on Day 1. Subjects from whom newly-obtained samples cannot be provided (e.g. inaccessible or subject safety concern) may submit an archived specimen only upon agreement from the Principal Investigator.
6) Have a performance status of 0 or 1 on the ECOG Performance Scale.
7) Demonstrate adequate organ function, all screening labs should be performed within 14 days of treatment initiation. Hematological: Absolute neutrophil count (ANC) >/= 1,500 /mcL; Platelets >/= 100,000 / mcL; Hemoglobin >/= 9 g/dL or >/= 5.6 mmol/L without transfusion or EPO dependency (within 7 days of assessment). Renal: Serum creatinine </= 1.5 X upper limit of normal (ULN) OR measured or calculated creatinine clearance >/= 60mL/min for subjects with creatinine levels > 1.5 X ULN. Hepatic: Serum total bilirubin </= 1.5 X ULN or direct bilirubin </= ULN for subjects with total bilirubin levels > 1.5 ULN; AST (SGOT) and ALT (SGPT) 9 </= 2.5 X ULN OR </= 5 X ULN for subjects with liver metastases.
8) contd from #7. Albumin >/= 2.5 g/dL. Coagulation: International Normalized Ratio (INR) or Prothrombin Time (PT) Activated Partial Thromboplastin Time (aPTT) </=1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants </= 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
9) Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
10) Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.
11) Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.
1) Is currently participating and receiving study therapy or has
participated in a study of an investigational agent and received study
therapy or used an investigational device within 4 weeks of the first
dose of treatment.
2) Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
3) Has a known history of active TB (Bacillus Tuberculosis)
4) Hypersensitivity to pembrolizumab, azacitidine, mannitol, or any of their excipients.
5) Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., </= Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.
6) Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., </= Grade 1 or at baseline) from adverse events due to a previously administered agent. - Note: Subjects with = Grade 2 neuropathy are an exception to this criterion and may qualify for the study. - Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
7) Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
8) Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis, which is excluded regardless of clinical stability.
9) Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
10) Has known history of, or any evidence of active, non-infectious pneumonitis.
11) Significant active cardiac disease within the previous 6 months including: - NYHA class 4 CHF - Unstable angina - Myocardial infarction
12) Has an active infection requiring systemic therapy.
13) Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject’s participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
14) Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
15) Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.
16) Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent [for Arm A only].
17) Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
18) Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
19) Has received a live vaccine within 30 days of planned start of study therapy.
Information and next steps
Melanoma and other malignant neoplasms of skin
Melanoma Medical Oncology
For general questions about clinical trials: